Nuvation Bio Q4 Revenue Soars 52.6% to $41.9M as Loss Narrows
Nuvation Bio reported a $0.11 per share adjusted loss in Q4, matching consensus and improving from a $0.15 loss a year earlier, while revenue jumped to $41.87 million, 52.6% above estimates and up from $5.71 million a year ago. Shares have dropped 34% year-to-date despite the strong top-line beat and narrowing loss.
1. Q4 Financial Results
Nuvation Bio posted an adjusted loss of $0.11 per share for Q4, in line with consensus and improved from a $0.15 loss in the year-ago quarter. The company has now beaten EPS estimates only once in the past four quarters, delivering an earnings surprise of -2.3%.
2. Revenue Jump and Drivers
Revenue surged to $41.87 million for the quarter, up from $5.71 million a year earlier and exceeding consensus by 52.6%. This marks the fourth consecutive quarter of revenue outperformance, driven by increased clinical trial activity and partnership milestones.
3. Stock Performance and Outlook
Shares have declined roughly 34% year-to-date despite the top-line strength and narrowing loss. Consensus estimates call for $0.05 EPS on $48.34 million revenue next quarter and a -$0.33 EPS on $197.35 million revenue for the fiscal year, with investor focus on upcoming management commentary and estimate revisions.